162 related articles for article (PubMed ID: 11792416)
41. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis.
Tyagi A; Agarwal R; Agarwal C
Oncogene; 2003 Mar; 22(9):1302-16. PubMed ID: 12618755
[TBL] [Abstract][Full Text] [Related]
42. Cell cycle arrest induced by the vitamin D(3) analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27.
Park WH; Seol JG; Kim ES; Jung CW; Lee CC; Binderup L; Koeffler HP; Kim BK; Lee YY
Exp Cell Res; 2000 Feb; 254(2):279-86. PubMed ID: 10640426
[TBL] [Abstract][Full Text] [Related]
43. Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat.
Ruef J; Meshel AS; Hu Z; Horaist C; Ballinger CA; Thompson LJ; Subbarao VD; Dumont JA; Patterson C
Circulation; 1999 Aug; 100(6):659-65. PubMed ID: 10441105
[TBL] [Abstract][Full Text] [Related]
44. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells.
Yi Q; Dabadghao S; Osterborg A; Bergenbrant S; Holm G
Blood; 1997 Sep; 90(5):1960-7. PubMed ID: 9292530
[TBL] [Abstract][Full Text] [Related]
45. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Shapiro GI; Supko JG; Patterson A; Lynch C; Lucca J; Zacarola PF; Muzikansky A; Wright JJ; Lynch TJ; Rollins BJ
Clin Cancer Res; 2001 Jun; 7(6):1590-9. PubMed ID: 11410495
[TBL] [Abstract][Full Text] [Related]
46. Human bone marrow stroma-dependent cell line MOLP-5 derived from a patient in leukaemic phase of multiple myeloma.
Matsuo Y; Drexler HG; Nishizaki C; Harashima A; Fukuda S; Kozuka T; Sezaki T; Orita K
Br J Haematol; 2000 Apr; 109(1):54-63. PubMed ID: 10848782
[TBL] [Abstract][Full Text] [Related]
47. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Motwani M; Li X; Schwartz GK
Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
[TBL] [Abstract][Full Text] [Related]
48. Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.
Gao N; Dai Y; Rahmani M; Dent P; Grant S
Mol Pharmacol; 2004 Oct; 66(4):956-63. PubMed ID: 15235103
[TBL] [Abstract][Full Text] [Related]
49. Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction.
Litz J; Carlson P; Warshamana-Greene GS; Grant S; Krystal GW
Clin Cancer Res; 2003 Oct; 9(12):4586-94. PubMed ID: 14555534
[TBL] [Abstract][Full Text] [Related]
50. Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL.
Fandy TE; Ross DD; Gore SD; Srivastava RK
Cancer Chemother Pharmacol; 2007 Aug; 60(3):313-9. PubMed ID: 17187253
[TBL] [Abstract][Full Text] [Related]
51. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.
Tan AR; Swain SM
Semin Oncol; 2002 Jun; 29(3 Suppl 11):77-85. PubMed ID: 12138401
[TBL] [Abstract][Full Text] [Related]
52. Fas/Fas ligand (FasL)-deregulated apoptosis and IL-6 insensitivity in highly malignant myeloma cells.
Frassanito MA; Silvestris F; Silvestris N; Cafforio P; Camarda G; Iodice G; Dammacco F
Clin Exp Immunol; 1998 Nov; 114(2):179-88. PubMed ID: 9822274
[TBL] [Abstract][Full Text] [Related]
53. [Flavopiridol, a cyclin-dependent kinase inhibitor].
Lansiaux A; Bailly C
Bull Cancer; 2000 Oct; 87(10):697-701. PubMed ID: 11084532
[No Abstract] [Full Text] [Related]
54. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.
Thomas JP; Tutsch KD; Cleary JF; Bailey HH; Arzoomanian R; Alberti D; Simon K; Feierabend C; Binger K; Marnocha R; Dresen A; Wilding G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):465-72. PubMed ID: 12451473
[TBL] [Abstract][Full Text] [Related]
55. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity.
Jiang J; Matranga CB; Cai D; Latham VM; Zhang X; Lowell AM; Martelli F; Shapiro GI
Cancer Res; 2003 Nov; 63(21):7410-22. PubMed ID: 14612540
[TBL] [Abstract][Full Text] [Related]
56. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol.
Li Y; Bhuiyan M; Alhasan S; Senderowicz AM; Sarkar FH
Clin Cancer Res; 2000 Jan; 6(1):223-9. PubMed ID: 10656453
[TBL] [Abstract][Full Text] [Related]
57. Relation between S-phase fraction of myeloma cells and anemia in patients with multiple myeloma.
Fosså A; Brandhorst D; Myklebust JH; Seeber S; Nowrousian MR
Exp Hematol; 1999 Nov; 27(11):1621-6. PubMed ID: 10560909
[TBL] [Abstract][Full Text] [Related]
58. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis.
Wittmann S; Bali P; Donapaty S; Nimmanapalli R; Guo F; Yamaguchi H; Huang M; Jove R; Wang HG; Bhalla K
Cancer Res; 2003 Jan; 63(1):93-9. PubMed ID: 12517783
[TBL] [Abstract][Full Text] [Related]
59. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation.
Rosato RR; Dai Y; Almenara JA; Maggio SC; Grant S
Leukemia; 2004 Nov; 18(11):1780-8. PubMed ID: 15385934
[TBL] [Abstract][Full Text] [Related]
60. [Detection of myeloma cells in the peripheral blood using flow cytometry].
Adam Z; Klabusay M; Vorlícek J; Hájek R
Vnitr Lek; 1997 Sep; 43(9):592-8. PubMed ID: 9750468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
